All‐cause mortality; · Ventilator‐associated pneumonia
Carbapenems showed no clear difference in all‐cause mortality; compared with non‐carbapenems (moderate certainty).
1 finding from 1 review
All‐cause mortality maximum · neonates and children with hospital‐acquired pneumonia
It is very uncertain whether cefepime changes all‐cause mortality Maximum compared with ceftazidime (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (high certainty).
1 finding from 1 review
All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Intervention not reported
Secondary ‐ All‐cause mortality · Patients with acute uncomplicated diverticulitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Secondary ‐ All‐cause mortality  · Patients with acute uncomplicated diverticulitis
The intervention showed no clear difference in secondary ‐ All‐cause mortality  (moderate certainty).
1 finding from 1 review